Literature DB >> 25517357

Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3' repair exonuclease 1 (TREX1).

Claudia Günther1, Nicole Berndt1, Christine Wolf2, Min Ae Lee-Kirsch2.   

Abstract

IMPORTANCE: Familial chilblain lupus is a rare, autosomal dominant form of lupus erythematosus characterized by cold-induced inflammatory lesions at acral locations presenting in early childhood. Familial chilblain lupus is usually caused by a mutation in TREX1 (3' repair exonuclease 1). OBSERVATIONS: We report on a family with dominant chilblain lupus segregating a novel TREX1 mutation (c.585C>G; H195Q) within the highly conserved exonuclease (Exo) III domain. Affected family members experienced cold-induced chilblain lesions of varying degrees, ranging from bluish-red infiltrations to mutilating necrotic ulcerations. In addition, all patients showed signs of systemic disease, such as arthritis, lymphopenia, or antinuclear antibodies. An increased expression of myxovirus resistance protein A in the skin and induction of interferon-stimulated genes in peripheral blood cells demonstrated activation of type I interferon. CONCLUSIONS AND RELEVANCE: This case further implicates type I interferon-dependent innate immune activation in the pathogenesis of TREX1-associated familial chilblain lupus. Unlike previously reported TREX1 mutations, which affect the Exo I or Exo II domains, the mutation presented here alters the Exo III domain, suggesting a particular role of mutations within the catalytic Exo domains in the pathogenesis of familial chilblain lupus. The high prevalence of extracutaneous manifestations, along with activation of type I interferon, underlines the systemic nature of familial chilblain lupus.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25517357     DOI: 10.1001/jamadermatol.2014.3438

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  21 in total

Review 1.  [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].

Authors:  C Günther; F Schmidt; N König; M A Lee-Kirsch
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

2.  Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.

Authors:  Jessica L Grieves; Jason M Fye; Scott Harvey; Jason M Grayson; Thomas Hollis; Fred W Perrino
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

Review 3.  [Familial chilblain lupus : Type 1 interferonopathy with model character].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

Review 4.  Non-Atherosclerotic Vascular Disease in Women.

Authors:  Lee Joseph; Esther S H Kim
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-09-14

Review 5.  Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?

Authors:  Christoph Fiehn
Journal:  Curr Rheumatol Rep       Date:  2017-08-26       Impact factor: 4.592

Review 6.  Human disease phenotypes associated with mutations in TREX1.

Authors:  Gillian I Rice; Mathieu P Rodero; Yanick J Crow
Journal:  J Clin Immunol       Date:  2015-03-04       Impact factor: 8.317

7.  [Genetics of lupus erythematosus].

Authors:  Claudia Günther
Journal:  Hautarzt       Date:  2015-02       Impact factor: 0.751

Review 8.  Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.

Authors:  Hanna Kim; Gina A Montealegre Sanchez; Raphaela Goldbach-Mansky
Journal:  J Mol Med (Berl)       Date:  2016-09-27       Impact factor: 4.599

9.  TREX-1-Related Disease Associated with the Presence of Cryofibrinogenemia.

Authors:  C Paradis; M Cadieux-Dion; C Meloche; M Gravel; J Paradis; A Des Roches; G Leclerc; P Cossette; P Begin
Journal:  J Clin Immunol       Date:  2019-01-26       Impact factor: 8.317

Review 10.  Type I interferonopathies in pediatric rheumatology.

Authors:  Stefano Volpi; Paolo Picco; Roberta Caorsi; Fabio Candotti; Marco Gattorno
Journal:  Pediatr Rheumatol Online J       Date:  2016-06-04       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.